We are live on ! Find out more
KALV icon

KalVista Pharmaceuticals

Delisted

KALV was delisted on the 10th of June, 2026.

32 hedge funds and large institutions have $7.65M invested in KalVista Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

0.67% more ownership

Funds ownership: 44.59% → 45.26% (+0.67%)

32% less funds holding

Funds holding: 47 → 32 (-15)

84% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 19

93% less capital inflows, than outflows

Capital inflows: $973K | Capital outflows: $14M

Holders
32
Holders Change
-15
Holders Change %
-31.91%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
8
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KALV Hedge Fund Activity: Q1 2016 in Review

32 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2016, worth a combined $7.65M — down 82% from $42.5M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KALV and 3 opened new positions — a net loss of 16 holders — while 8 trimmed existing stakes and 10 added.

The largest buyer was Goldman Sachs, adding an estimated $633K. The largest seller was Franklin Resources, exiting entirely with an estimated $5.24M sold.

  • 32 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2016, down from 47 in Q4 2015.
  • Funds reported $7.65M of KalVista Pharmaceuticals stock for Q1 2016, down 82% quarter-over-quarter.
  • 3 funds opened new KalVista Pharmaceuticals positions in Q1 2016 and 19 closed out, a net change of -16 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2016 was Goldman Sachs, an estimated $633K added.
  • The largest KalVista Pharmaceuticals seller in Q1 2016 was Franklin Resources, an estimated $5.24M sold.

Based on aggregated 13F filings for Q1 2016.